Form D · Biotechnology
SenGenix, Inc.
Durham, NC · CIK 0001586429
Offering snapshot reported Oct 16, 2017 · SEC filing
- Reported sold
- $6.27M Offering amount: $6.27M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 2, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 16, 2017 | Initial | $6,269,658 | No comparison | 18 | SEC filing |
| Sep 15, 2016 | Initial | $1,500,000 | No comparison | 11 | SEC filing |
| Oct 27, 2015 | Initial | $1,050,000 | No comparison | 7 | SEC filing |
| Jul 7, 2014 | Amendment | $1,969,801 | $1,519,801vs Sep 13, 2013 | 15 | SEC filing |
| Sep 13, 2013 | Initial | $450,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-296713
Source: Form D, filed Oct 16, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lawrence Cohen | Director |
| Sandra E. Cummings | Director, Executive |
| Homme Hellinga | Director, Executive |
| Ralph Snyderman | Director |
| Richard S. Surwit | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1738 Hillandale Road Suite 102
Durham, NC, 27705
Durham, NC, 27705